The three-year analysis enrolled adults with prediabetes and overweight or obesity (n = 1,032) [2]. The different approved uses of Zepbound and Mounjaro matter when a clinician considers why to prescribe tirzepatide. The trial does not establish that everyone with prediabetes should take it.
What happened during and after treatment
At 176 weeks, 1.3% of the pooled tirzepatide groups had developed type 2 diabetes, compared with 13.3% on placebo [2]. After 17 weeks off treatment, cumulative figures were 2.4% and 13.7%. Studies of weight after stopping a GLP-1 address a related question about how treatment effects change after withdrawal. This trial followed participants for only 17 weeks after treatment stopped.
How well did glucose tests predict progression?
A follow-up analysis examined three test thresholds among trial participants who had already qualified as having prediabetes [1]. In the placebo group, diabetes developed in 15% of those flagged by the one-hour glucose test. The figures were 37% for fasting glucose and 19% for HbA1c. The one-hour threshold captured more eventual cases, but it also flagged more people who did not develop diabetes. These estimates apply to this trial population and its thresholds.
What to discuss with a clinician
US diabetes guidance recommends structured prevention programs for adults with overweight or obesity at high risk of type 2 diabetes [3]. It also recognizes the role of weight-management medications when appropriate. Zepbound’s FDA label covers weight management in eligible people and obstructive sleep apnea in certain adults with obesity [4]. Prediabetes itself is outside those indications.